Nuix rev for FY23 was $182.5m, with the growth we know about from the May update that FY24 EBITDA is up 35% and ACV is up 10% on 23 + the one-off insurance sugar-hit. So a 20% Nett Revenue growth is not unreasonable.
What is the PE for this category on $220m Rev and growing conservatively at 15-20% PA?
DYOR.
Ann: FY24 Further Earnings Update, page-110
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.28 |
Change
-0.270(3.58%) |
Mkt cap ! $2.392B | |||
| Open | High | Low | Value | Volume |
| $7.61 | $7.70 | $7.27 | $8.034M | 1.081M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 7585 | $7.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.34 | 7975 | 2 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| NXL (ASX) Chart |